{"id":1298,"date":"2026-01-24T08:35:20","date_gmt":"2026-01-24T08:35:20","guid":{"rendered":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/2026\/01\/24\/transient-hypothyroidsm-induced-by-sunitinib-an-anti-tumoral-thyrosine-kinase-selective-inhibitor-is\/"},"modified":"2026-01-24T08:35:20","modified_gmt":"2026-01-24T08:35:20","slug":"transient-hypothyroidsm-induced-by-sunitinib-an-anti-tumoral-thyrosine-kinase-selective-inhibitor-is","status":"publish","type":"post","link":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/2026\/01\/24\/transient-hypothyroidsm-induced-by-sunitinib-an-anti-tumoral-thyrosine-kinase-selective-inhibitor-is\/","title":{"rendered":"TRANSIENT HYPOTHYROIDSM INDUCED BY SUNITINIB, AN ANTI-TUMORAL THYROSINE-KINASE SELECTIVE INHIBITOR, IS ASSOCIATED WITH OTHER ENDOCRINE DYSFUNCTIONS"},"content":{"rendered":"<div class=\"article-authors\">Mannavola D.<sup>1<\/sup>, Vannucchi G.<sup>1<\/sup>, Covelli D.<sup>1<\/sup>, Coco P.<sup>2<\/sup>, Bertulli R.<sup>2<\/sup>, Casali P.<sup>2<\/sup>, Beck-Peccoz P.<sup>1<\/sup>, Fugazzola L.<sup>1<\/sup><\/div>\n<div class=\"article-institutes\"><sup>1<\/sup>Department of Medical Sciences, Endocrine Unit, University of Milan, IRCCS Fondazione Policlinico, MIlan, Italy, <sup>2<\/sup>Department of Oncology, Istituto Nazionale dei Tumori, Milan, Italy<\/div>\n<div class=\"article-abstract\">\n<h2>Abstract<\/h2>\n<p>Sunitinib is a multitarget inhibitor of tyrosine-kinases used in different human cancers with a high efficacy and few mild side effects. Among these, a transient hypothyroidism was found to occur in up to 70% of patients. In order to evaluate the possible association with other endocrine alterations, gonadal, adrenal and parathyroid function was evaluated in 12 patients (7 M, 5 F) who developed hypothyroidism during Sunitinib administration for a gastrointestinal tumor. The drug was orally given according to the 6-week cycle scheme: 4 weeks of daily administration (ON) and 2 weeks of withdrawal (OFF). Blood samples were collected on the last day of both ON and OFF periods. Serum ACTH and cortisol, PTH and calcium, LH and testosterone were measured. After 1 to 6 cycles of treatment, increased ACTH levels were recorded in 58% of hypothyroid patients, and increased PTH levels in the 50%. In 33% of patients, a concomitant elevation of TSH, ACTH and PTH was recorded. Increased LH levels were associated with high TSH in 43% of males. As observed for TSH, in all patients ACTH, PTH and LH levels increased during the ON periods and decreased during the OFF periods. Differently from TSH, serum levels of ACTH, PTH and LH always remained in the normal range. No variations in cortisol, calcium or testosterone levels were recorded during the ON and OFF periods. In conclusion, this study first demonstrates an increase of ACTH, PTH and LH levels in about 40% of patients with Sunitinib induced hypothyroidism. The mechanism underlying this complex hormonal alteration is presently unknown. Further studies are needed to identify a possible common response element targeted by Sunitinib in the promoter regions of these genes. <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Mannavola D.1, Vannucchi G.1, Covelli D.1, Coco P.2, Bertulli R.2, Casali P.2, Beck-Peccoz P.1, Fugazzola L.1 1Department of Medical Sciences, Endocrine Unit, University of Milan, IRCCS Fondazione Policlinico, MIlan, Italy, 2Department of Oncology, Istituto Nazionale dei Tumori, Milan, Italy Abstract Sunitinib is a multitarget inhibitor of tyrosine-kinases used in different human cancers with a high <a class=\"read-more\" href=\"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/2026\/01\/24\/transient-hypothyroidsm-induced-by-sunitinib-an-anti-tumoral-thyrosine-kinase-selective-inhibitor-is\/\">Read More<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[45,2,9],"tags":[],"class_list":["post-1298","post","type-post","status-publish","format-standard","hentry","category-volume-7-issue-3","category-journal-articles","category-volume-7"],"_links":{"self":[{"href":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/wp-json\/wp\/v2\/posts\/1298","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/wp-json\/wp\/v2\/comments?post=1298"}],"version-history":[{"count":0,"href":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/wp-json\/wp\/v2\/posts\/1298\/revisions"}],"wp:attachment":[{"href":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/wp-json\/wp\/v2\/media?parent=1298"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/wp-json\/wp\/v2\/categories?post=1298"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/wp-json\/wp\/v2\/tags?post=1298"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}